<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="courier ; font-style : italic;} Can Respir JCan. Respir. JCRJCanadian" exact="Respiratory" post="Journal1198-22411916-7245Hindawi pmcid: 7479474 pmid: 32934758 doi: 10.1155/2020/1401053 : Research"/>
 <result pre="Journal1198-22411916-7245Hindawi pmcid: 7479474 pmid: 32934758 doi: 10.1155/2020/1401053 : Research Article" exact="Tuberculosis" post="and COVID-19: Lessons from the Past Viral Outbreaks and"/>
 <result pre=": Research Article Tuberculosis and COVID-19: Lessons from the Past" exact="Viral" post="Outbreaks and Possible Future Outcomes Crisan-DabijaRadu1GrigorescuCristina2PavelCristina-Alice3ArteneBogdan4https://orcid.org/0000-0002-0597-8839PopaIolanda Valentinaiolivp@gmail.com56CernomazAndrei7https://orcid.org/0000-0002-3424-1588BurlacuAlexandru46[], 1[], 2[],"/>
 <result pre="work is properly cited. Abstract Background The threat of contagious" exact="infectious diseases" post="is constantly evolving as demographic explosion, travel globalization, and"/>
 <result pre="the risk of spreading pathogens, leading to accelerated changes in" exact="disease" post="landscape. Of particular interest is the aftermath of superimposing"/>
 <result pre="disease landscape. Of particular interest is the aftermath of superimposing" exact="viral" post="epidemics (especially SARS-CoV-2) over long-standing diseases, such as tuberculosis"/>
 <result pre="superimposing viral epidemics (especially SARS-CoV-2) over long-standing diseases, such as" exact="tuberculosis" post="(TB), which remains a significant disease for public health"/>
 <result pre="long-standing diseases, such as tuberculosis (TB), which remains a significant" exact="disease" post="for public health worldwide and especially in emerging economies."/>
 <result pre="coronaviruses) and influenza pandemic/seasonal outbreaks have taught the importance of" exact="infection" post="control to avoid the severe impact on TB patients."/>
 <result pre="and diagnostic reliability in the context of coinfection. Conclusions Because" exact="viral" post="respiratory infections and TB impede the host's immune responses,"/>
 <result pre="diagnostic reliability in the context of coinfection. Conclusions Because viral" exact="respiratory" post="infections and TB impede the host's immune responses, it"/>
 <result pre="reliability in the context of coinfection. Conclusions Because viral respiratory" exact="infections" post="and TB impede the host's immune responses, it can"/>
 <result pre="Development FundMySMIS 107124 1. Introduction The global threat of contagious" exact="infectious diseases," post="particularly tuberculosis (TB), has long concerned authorities in charge"/>
 <result pre="1. Introduction The global threat of contagious infectious diseases, particularly" exact="tuberculosis" post="(TB), has long concerned authorities in charge of public"/>
 <result pre="of death worldwide and the leading cause of a single" exact="infectious" post="agent [3, 4]), especially in most middle-income and emerging-economy"/>
 <result pre="downward trend since then, 54.5/100 000 in 2016, and 54.2%" exact="lower" post="than in 2002 [4, 5]. A series of factors"/>
 <result pre="Romania, namely, a large number of severe forms, cases with" exact="multidrug-resistant tuberculosis" post="(MDR-TB) and extensively drug-resistant TB (XDR-TB), HIV coinfection, and"/>
 <result pre="namely, a large number of severe forms, cases with multidrug-resistant" exact="tuberculosis" post="(MDR-TB) and extensively drug-resistant TB (XDR-TB), HIV coinfection, and"/>
 <result pre="between 2012 and 2015, with a threefold increase [4]. Influenza" exact="infection" post="may promote the progression of latent Mycobacterium tuberculosis (MTB)"/>
 <result pre="[4]. Influenza infection may promote the progression of latent Mycobacterium" exact="tuberculosis" post="(MTB) infection to active TB, alter the clinical presentation"/>
 <result pre="infection may promote the progression of latent Mycobacterium tuberculosis (MTB)" exact="infection" post="to active TB, alter the clinical presentation of TB,"/>
 <result pre="alter the clinical presentation of TB, and also possibly exacerbate" exact="pulmonary" post="TB (PTB) [6]. Both influenza and tuberculosis hinder host"/>
 <result pre="also possibly exacerbate pulmonary TB (PTB) [6]. Both influenza and" exact="tuberculosis" post="hinder host immune responses. Specifically, influenza can impair T-cell"/>
 <result pre="can impair T-cell immunity and weaken innate immune responses against" exact="secondary" post="bacterial infections [6, 7]. This deleterious synergism of viral"/>
 <result pre="impair T-cell immunity and weaken innate immune responses against secondary" exact="bacterial infections" post="[6, 7]. This deleterious synergism of viral and bacterial"/>
 <result pre="T-cell immunity and weaken innate immune responses against secondary bacterial" exact="infections" post="[6, 7]. This deleterious synergism of viral and bacterial"/>
 <result pre="against secondary bacterial infections [6, 7]. This deleterious synergism of" exact="viral" post="and bacterial infections increases the risk of influenza-associated mortality,"/>
 <result pre="bacterial infections [6, 7]. This deleterious synergism of viral and" exact="bacterial infections" post="increases the risk of influenza-associated mortality, and patients with"/>
 <result pre="infections [6, 7]. This deleterious synergism of viral and bacterial" exact="infections" post="increases the risk of influenza-associated mortality, and patients with"/>
 <result pre="and patients with PTB may increase the severity of influenza" exact="disease" post="and death due to chronic lung disease and immunosuppression."/>
 <result pre="increase the severity of influenza disease and death due to" exact="chronic" post="lung disease and immunosuppression. Epidemiologic data suggest an increased"/>
 <result pre="the severity of influenza disease and death due to chronic" exact="lung disease" post="and immunosuppression. Epidemiologic data suggest an increased rate of"/>
 <result pre="severity of influenza disease and death due to chronic lung" exact="disease" post="and immunosuppression. Epidemiologic data suggest an increased rate of"/>
 <result pre="data suggest an increased rate of influenza or severe influenza-associated" exact="disease" post="in patients with TB during influenza pandemics [6, 8,"/>
 <result pre="epidemics [10] compared with non-TB individuals. 2. Objectives Individuals with" exact="chronic" post="respiratory infections, including TB, are first to experience the"/>
 <result pre="[10] compared with non-TB individuals. 2. Objectives Individuals with chronic" exact="respiratory" post="infections, including TB, are first to experience the adverse"/>
 <result pre="in the healthcare setting [11, 12]. Given that both coronavirus" exact="disease" post="2019 (COVID-19) and TB become important causes of mortality"/>
 <result pre="have been described three human coronaviruses known to cause fatal" exact="respiratory" post="diseases: The severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV,"/>
 <result pre="human coronaviruses known to cause fatal respiratory diseases: The severe" exact="acute" post="respiratory syndrome (SARS) coronavirus (SARS-CoV, now known as SARS-CoV-1)"/>
 <result pre="coronaviruses known to cause fatal respiratory diseases: The severe acute" exact="respiratory" post="syndrome (SARS) coronavirus (SARS-CoV, now known as SARS-CoV-1) that"/>
 <result pre="known to cause fatal respiratory diseases: The severe acute respiratory" exact="syndrome" post="(SARS) coronavirus (SARS-CoV, now known as SARS-CoV-1) that led"/>
 <result pre="led to a global epidemic in 2002 [13] The Middle-East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) which was discovered in 2012 and"/>
 <result pre="to a global epidemic in 2002 [13] The Middle-East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) which was discovered in 2012 and still"/>
 <result pre="only three months since the first declared case of COVID-19" exact="pneumonia" post="[16]. Its high transmissibility rate reminds of the 1918-19"/>
 <result pre="the striking resemblance of pathological features documented in COVID-19 associated" exact="acute" post="respiratory distress syndrome (ARDS) and H7N9-induced ARDS [18]. Also,"/>
 <result pre="striking resemblance of pathological features documented in COVID-19 associated acute" exact="respiratory" post="distress syndrome (ARDS) and H7N9-induced ARDS [18]. Also, it"/>
 <result pre="of pathological features documented in COVID-19 associated acute respiratory distress" exact="syndrome" post="(ARDS) and H7N9-induced ARDS [18]. Also, it has been"/>
 <result pre="have shown that, in a patient with TB, induction of" exact="type I" post="interferons (IFNs) determined by influenza infection could be detrimental"/>
 <result pre="TB, induction of type I interferons (IFNs) determined by influenza" exact="infection" post="could be detrimental [11], impeding the immune-competent host's ability"/>
 <result pre="be detrimental [11], impeding the immune-competent host's ability to limit" exact="bacterial" post="replication. Thus it promotes the infection [19] and precipitates"/>
 <result pre="host's ability to limit bacterial replication. Thus it promotes the" exact="infection" post="[19] and precipitates TB mortality rate (pneumonia and influenza"/>
 <result pre="severity [20, 21]. One murine model demonstrated that although influenza" exact="infection" post="increased the IFN-Î³ secretion, it had little effect on"/>
 <result pre="infection increased the IFN-Î³ secretion, it had little effect on" exact="bacterial" post="load in chronically infected mice with BCG [21]. Half"/>
 <result pre="highlighted that to contain the epidemic, the correct management of" exact="symptomatic" post="patients (within and outside the hospital) was critical [22]."/>
 <result pre="patients (within and outside the hospital) was critical [22]. The" exact="secondary" post="transmission within Vancouver (Canada) was stopped due to the"/>
 <result pre="further and hospital clusters [22, 23]. Also, inappropriate implementation of" exact="infection" post="control strategies in Singapore led to massive healthcare personnel"/>
 <result pre="infection control strategies in Singapore led to massive healthcare personnel" exact="infection" post="(half of the SARS cases were among healthcare workers)"/>
 <result pre="or Taiwan [24, 25], all with known TB patients that" exact="acquired" post="SARS and in individuals that developed TB after recovery"/>
 <result pre="individuals that developed TB after recovery from SARS [25]. The" exact="transient" post="immunosuppression characterized both conditions [26], a reason for poorer"/>
 <result pre="a reason for poorer IgG antibody response and a delayed" exact="viral" post="clearance in coinfected SARS patients [24]. Also, the use"/>
 <result pre="taken (especially in hospitals) to limit the transmission of the" exact="disease" post="to naÃ¯ve patients. However, overcrowding hospitals are prone to"/>
 <result pre="hospitals are prone to mistakes. Known-TB patients from China supposedly" exact="acquired" post="SARS due to exposure to SARS patients from the"/>
 <result pre="without complications, SARS coinfection on TB cases led to significantly" exact="lower" post="mean CD4+ and CD8â€‰+â€‰T cells and undetectable or unusually"/>
 <result pre="unusually low antibody levels after SARS recovery [24]. Also, the" exact="viral" post="excretion was two times longer in sputum and five"/>
 <result pre="epidemic from Singapore, SARS cases were reported developing active PTB" exact="short" post="after recovering from SARS [25], data compatible with previous"/>
 <result pre="on mice regarding the suppression of cellular immunity after a" exact="viral infection" post="[11]. There is also data on MERS-CoV augmenting TB"/>
 <result pre="mice regarding the suppression of cellular immunity after a viral" exact="infection" post="[11]. There is also data on MERS-CoV augmenting TB"/>
 <result pre="among TB cases, hospital treatment for TB patients should be" exact="limited" post="to severe cases. 4.2. Is Coinfection More Severe? Pathological"/>
 <result pre="to the one of SARS-CoV-1. Substantial evidence suggests that SARS-CoV-2" exact="infection" post="could initiate an aggressive inflammation by increasing cytokines secretion"/>
 <result pre="by increasing cytokines secretion such as interleukin-1Î² (IL-1Î²), interferon-Î³ (IFN-Î³)," exact="tumor" post="necrosis factor-Î± (TNF-Î±), interleukin-2 (IL-2), interleukin-4 (IL-4), and interleukin-10"/>
 <result pre="(IL-4), and interleukin-10 (IL-10), their plasma levels being associated with" exact="disease" post="severity, leading to a so-called â€œcytokine storm,â€� thus explaining"/>
 <result pre="to a so-called â€œcytokine storm,â€� thus explaining some young adults'" exact="disease" post="severity [29]. Immune system hyperreaction was also described in"/>
 <result pre="might be premature, few studies proved that influenza aggravated the" exact="pulmonary" post="status of individuals with TB so that latent TB"/>
 <result pre="and various lesions might progress, leading to further deterioration of" exact="pulmonary" post="function [9]. In this regard, a mouse coronavirus model"/>
 <result pre="with TB in 23 patients, raising the suspicion that SARS-CoV-2" exact="infection" post="might boost the development of active TB. However, this"/>
 <result pre="However, this remains purely speculative as individuals with latent TB" exact="infection" post="were not followed up over time [30]. Cytokines have"/>
 <result pre="host resistance to TB infection, being first demonstrated in murine" exact="infection" post="models [19] and later validated by severe mycobacterial disease"/>
 <result pre="in murine infection models [19] and later validated by severe" exact="mycobacterial disease" post="findings in patients with mutations in the IFN-Î³ and"/>
 <result pre="murine infection models [19] and later validated by severe mycobacterial" exact="disease" post="findings in patients with mutations in the IFN-Î³ and"/>
 <result pre="with mutations in the IFN-Î³ and IL-12 signaling pathways and" exact="rheumatoid arthritis" post="or Crohn's disease patients treated with TNF-Î± blockade [19,"/>
 <result pre="mutations in the IFN-Î³ and IL-12 signaling pathways and rheumatoid" exact="arthritis" post="or Crohn's disease patients treated with TNF-Î± blockade [19,"/>
 <result pre="the IFN-Î³ and IL-12 signaling pathways and rheumatoid arthritis or" exact="Crohn's disease" post="patients treated with TNF-Î± blockade [19, 31]. Since the"/>
 <result pre="IFN-Î³ and IL-12 signaling pathways and rheumatoid arthritis or Crohn's" exact="disease" post="patients treated with TNF-Î± blockade [19, 31]. Since the"/>
 <result pre="31]. Since the SARS-CoV-2 is a newly discovered pathogen (first" exact="infection" post="being reported in December 2019) [29], little data about"/>
 <result pre="status might play a role in the development of severe" exact="acute" post="respiratory syndrome in SARS-CoV-2 coinfection, considering the cases described"/>
 <result pre="might play a role in the development of severe acute" exact="respiratory" post="syndrome in SARS-CoV-2 coinfection, considering the cases described in"/>
 <result pre="play a role in the development of severe acute respiratory" exact="syndrome" post="in SARS-CoV-2 coinfection, considering the cases described in China"/>
 <result pre="contrary, 20 patients with TB and COVID-19 had a rather" exact="benign" post="clinical course of the coinfection, with only one patient"/>
 <result pre="coinfection, with only one patient that died. TB lesions at" exact="chest" post="X-ray were not aggravated, and only four patients had"/>
 <result pre="aggravated, and only four patients had signs of newly developed" exact="pneumonia" post="[37]. One should keep in mind that the existence"/>
 <result pre="should keep in mind that the existence of underlying conditions," exact="autoimmune diseases," post="poor hygiene, and overcrowding is all known as risk"/>
 <result pre="treatments [41]. Discontinuation risks and other challenges faced by the" exact="tuberculosis" post="clinical trials in the face of COVID-19 have been"/>
 <result pre="unfortunate outcome in people 25â€&quot;35 years old. Although there is" exact="limited" post="data on MTB and COVID-19 coinfection, one could reasonably"/>
 <result pre="research was done to find a vaccine to prevent the" exact="disease" post="[44]. Different vaccine types were tested: inactivated or live-attenuated"/>
 <result pre="or live-attenuated virus, DNA-based vaccines, recombinant proteins, virus-like particles, and" exact="viral" post="vectors with some promising efficiency, but with neither being"/>
 <result pre="it was observed that BCG-vaccinated newborns had a three times" exact="lower" post="mortality rate in their first year of life than"/>
 <result pre="the unvaccinated ones [51]. Later was noted a decrease in" exact="infectious" post="morbidities, protecting both mice (against secondary fungal or parasitic"/>
 <result pre="noted a decrease in infectious morbidities, protecting both mice (against" exact="secondary" post="fungal or parasitic infections with Candida albicans or Schistosoma"/>
 <result pre="infectious morbidities, protecting both mice (against secondary fungal or parasitic" exact="infections" post="with Candida albicans or Schistosoma mansoni through tissue macrophages"/>
 <result pre="Schistosoma mansoni through tissue macrophages activation) [49] and infants (against" exact="acute" post="lower respiratory infections). Thus, the risk of acute lower"/>
 <result pre="mansoni through tissue macrophages activation) [49] and infants (against acute" exact="lower" post="respiratory infections). Thus, the risk of acute lower respiratory"/>
 <result pre="through tissue macrophages activation) [49] and infants (against acute lower" exact="respiratory" post="infections). Thus, the risk of acute lower respiratory infections"/>
 <result pre="infants (against acute lower respiratory infections). Thus, the risk of" exact="acute" post="lower respiratory infections in BCG-vaccinated infants seemed to be"/>
 <result pre="(against acute lower respiratory infections). Thus, the risk of acute" exact="lower" post="respiratory infections in BCG-vaccinated infants seemed to be 37%"/>
 <result pre="acute lower respiratory infections). Thus, the risk of acute lower" exact="respiratory" post="infections in BCG-vaccinated infants seemed to be 37% lower"/>
 <result pre="lower respiratory infections). Thus, the risk of acute lower respiratory" exact="infections" post="in BCG-vaccinated infants seemed to be 37% lower than"/>
 <result pre="lower respiratory infections in BCG-vaccinated infants seemed to be 37%" exact="lower" post="than in unvaccinated controls among children &amp;lt;5 years old"/>
 <result pre="the chance of a BCG vaccine received decades ago in" exact="childhood" post="could influence the course of one pandemic in adulthood"/>
 <result pre="in mind that the United States delayed the implementation of" exact="infection" post="control strategies (that could avoid superspreading events). There still"/>
 <result pre="the BCG vaccine is contemplated as a potential candidate against" exact="respiratory" post="viruses [48]. Moreover, Muldron Children's Research Institute from Australia"/>
 <result pre="healthcare workers' BCG vaccination will have any impact on SARS-CoV-2" exact="infection" post="(BCG Vaccination to Protect Healthcare Workers against COVID-19, BRACE,"/>
 <result pre="the Aerosol Inhaled Route and the Intramuscular Route in Healthy" exact="Adult" post="Subjects, NCT04121494). The University of Oxford appears to be"/>
 <result pre="Determine the Efficacy, Safety, and Immunogenicity of the Candidate Coronavirus" exact="Disease" post="(COVID-19) Vaccine ChAdOx1 nCoV-19, NCT04327206). It is noted that"/>
 <result pre="based on S protein are also considered for preventing SARS-CoV-2" exact="infection" post="[47, 58, 59]. Novel methods are emerging such as"/>
 <result pre="that refers to the process of constructing vaccines by detecting" exact="viral" post="antigens through genomic analysis using bioinformatics tools. Reverse vaccinology"/>
 <result pre="design potential subunit vaccines against SARS-CoV-2 using the highly antigenic" exact="viral" post="proteins and epitopes. Suggested vaccine constructs appeared to confer"/>
 <result pre="the Diagnosis of the Other?) TB and COVID-19 are mainly" exact="respiratory" post="diseases that primarily affect the lungs; however, the onset"/>
 <result pre="as cough, fever, or shortness of breath and various radiological" exact="pulmonary" post="lesions [4, 22], accurate diagnostic tests should be made"/>
 <result pre="an impaired immune system, such as in a concurrent severe" exact="infection" post="[65, 66]. Increased age, low peripheral lymphocyte count, high"/>
 <result pre="system, such as in a concurrent severe infection [65, 66]." exact="Increased" post="age, low peripheral lymphocyte count, high body mass index,"/>
 <result pre="in a concurrent severe infection [65, 66]. Increased age, low" exact="peripheral" post="lymphocyte count, high body mass index, and immunosuppressive therapies"/>
 <result pre="[67]. It has been observed that high CRP and low" exact="peripheral" post="lymphocyte counts could occur within a few days of"/>
 <result pre="further transmission [13]. Conventional methods such as assays for detecting" exact="viral" post="antigens or antiviral antibodies and newer methods of diagnosis"/>
 <result pre="clinical onset (fever, dry cough, dyspnoea and radiological findings of" exact="bilateral" post="infiltrates, and even pleural effusion and cavitation) [69], doctors"/>
 <result pre="cough, dyspnoea and radiological findings of bilateral infiltrates, and even" exact="pleural" post="effusion and cavitation) [69], doctors may either be facing"/>
 <result pre="either be facing a steep differential diagnostic or not consider" exact="tuberculosis" post="at all. Considering the sudden onset of the SARS-CoV-2"/>
 <result pre="countries struggled to quickly find a possible treatment to prevent" exact="respiratory" post="failures and deaths, especially among patients with respiratory comorbidities."/>
 <result pre="to prevent respiratory failures and deaths, especially among patients with" exact="respiratory" post="comorbidities. Also, since its fatal dynamics, there is no"/>
 <result pre="the first instance. It seems that an antiviral used for" exact="HIV infection," post="composed of two protease inhibitors (lopinavir and ritonavir), would"/>
 <result pre="a recommendation in the treatment of the COVID-19 in a" exact="short" post="time [13]. Other compounds, such as redexivir, favivir, ribavirin,"/>
 <result pre="to shorten the duration of SARS-CoV-2 viremia by reducing the" exact="viral" post="load [68]. However, hydroxychloroquine has also been associated with"/>
 <result pre="been associated with a higher risk of nontuberculous mycobacterial (NTM)" exact="infection" post="in rheumatoid arthritis patients [14]. 4.4.1. Key Points Coinfection"/>
 <result pre="with a higher risk of nontuberculous mycobacterial (NTM) infection in" exact="rheumatoid arthritis" post="patients [14]. 4.4.1. Key Points Coinfection of TB and"/>
 <result pre="a higher risk of nontuberculous mycobacterial (NTM) infection in rheumatoid" exact="arthritis" post="patients [14]. 4.4.1. Key Points Coinfection of TB and"/>
 <result pre="of TB and SARS-CoV-2 may be challenging to diagnose. SARS-CoV-2" exact="infection" post="may mask the clinical and radiological active TB. Patients"/>
 <result pre="proposed treatment for COVID-19 may be at risk for the" exact="infection" post="with NTM. 5. Conclusions Because viral respiratory infections and"/>
 <result pre="at risk for the infection with NTM. 5. Conclusions Because" exact="viral" post="respiratory infections and TB impede the host's immune responses,"/>
 <result pre="risk for the infection with NTM. 5. Conclusions Because viral" exact="respiratory" post="infections and TB impede the host's immune responses, their"/>
 <result pre="for the infection with NTM. 5. Conclusions Because viral respiratory" exact="infections" post="and TB impede the host's immune responses, their lethal"/>
 <result pre="affects both sides of these patients: rapid development of severe" exact="acute" post="respiratory syndrome through cytokine-mediated immune response and increased risk"/>
 <result pre="both sides of these patients: rapid development of severe acute" exact="respiratory" post="syndrome through cytokine-mediated immune response and increased risk of"/>
 <result pre="sides of these patients: rapid development of severe acute respiratory" exact="syndrome" post="through cytokine-mediated immune response and increased risk of tuberculosis"/>
 <result pre="respiratory syndrome through cytokine-mediated immune response and increased risk of" exact="tuberculosis" post="reactivation. As a lesson from previous outbreaks, hospital treatment"/>
 <result pre="a lesson from previous outbreaks, hospital treatment for patients with" exact="tuberculosis" post="should be limited to severe cases, to prevent the"/>
 <result pre="previous outbreaks, hospital treatment for patients with tuberculosis should be" exact="limited" post="to severe cases, to prevent the spread of SARS-CoV-2"/>
 <result pre="3BeautÃ©J.DaraM.ColombaniP.EhsaniS.GozalovO.HovanesyanA.Tuberculosis Surveillance and Monitoring in Europe 20172017150Stockholm, SwedenEuropean Centre for" exact="Disease" post="Prevention and Control 4GolliA.-L.NiÅ£uM. F.TurcuF.PopescuM.Ciobanu-MitracheL.OlteanuM.Tuberculosis remains a public health"/>
 <result pre="remains a public health problem in RomaniaThe International Journal of" exact="Tuberculosis" post="and Lung Disease201923222623110.5588/ijtld.18.027030808456 5NiÅ¢uF. M.OlteanuM.StrebaC. Tet al.Tuberculosis and its"/>
 <result pre="al.Tuberculosis and its particularities in Romania and worldwideRomanian journal of" exact="morphology" post="and embryology=Revue roumaine de morphologie et embryologie201758238539228730222 6WalazaS.CohenC.TempiaS.et al.Influenza"/>
 <result pre="and embryology=Revue roumaine de morphologie et embryologie201758238539228730222 6WalazaS.CohenC.TempiaS.et al.Influenza and" exact="tuberculosis" post="co-infection: a systematic reviewInfluenza and Other Respiratory Viruses2020141779110.1111/irv.1267031568678 7SmallC.-L.ShalerC."/>
 <result pre="6WalazaS.CohenC.TempiaS.et al.Influenza and tuberculosis co-infection: a systematic reviewInfluenza and Other" exact="Respiratory" post="Viruses2020141779110.1111/irv.1267031568678 7SmallC.-L.ShalerC. R.McCormickS.et al.Influenza infection leads to increased susceptibility"/>
 <result pre="a systematic reviewInfluenza and Other Respiratory Viruses2020141779110.1111/irv.1267031568678 7SmallC.-L.ShalerC. R.McCormickS.et al.Influenza" exact="infection" post="leads to increased susceptibility to subsequent bacterial superinfection by"/>
 <result pre="Other Respiratory Viruses2020141779110.1111/irv.1267031568678 7SmallC.-L.ShalerC. R.McCormickS.et al.Influenza infection leads to increased" exact="susceptibility to" post="subsequent bacterial superinfection by impairing NK cell responses in"/>
 <result pre="7SmallC.-L.ShalerC. R.McCormickS.et al.Influenza infection leads to increased susceptibility to subsequent" exact="bacterial" post="superinfection by impairing NK cell responses in the lungThe"/>
 <result pre="of Immunology201018442048205610.4049/jimmunol.090277220083661 8NoymerA.The 1918 influenza pandemic hastened the decline of" exact="tuberculosis" post="in the United States: an age, period, cohort analysisVaccine2011292B38B4110.1016/j.vaccine.2011.02.05321757102"/>
 <result pre="United States: an age, period, cohort analysisVaccine2011292B38B4110.1016/j.vaccine.2011.02.05321757102 9OeiW.NishiuraH.The relationship between" exact="tuberculosis" post="and influenza death during the influenza (H1N1) pandemic from"/>
 <result pre="in Medicine2012201210.1155/2012/124861 10WalazaS.CohenC.NanooA.CohenA. L.McAnerneyJ.von MollendorfC.Excess mortality associated with influenza among" exact="tuberculosis" post="deaths in South Africa, 1999â€&quot;2009PLoS One201510610.1371/journal.pone.0129173 11RedfordP. S.Mayer-BarberK. D.McNabF."/>
 <result pre="S.Mayer-BarberK. D.McNabF. W.et al.Influenza A virus impairs control of Mycobacterium" exact="tuberculosis" post="coinfection through a type I interferon receptor-dependent pathwayThe Journal"/>
 <result pre="A virus impairs control of Mycobacterium tuberculosis coinfection through a" exact="type I" post="interferon receptor-dependent pathwayThe Journal of Infectious Diseases2014209227027410.1093/infdis/jit42423935205 12OrganisationW. H.WHO"/>
 <result pre="coinfection through a type I interferon receptor-dependent pathwayThe Journal of" exact="Infectious" post="Diseases2014209227027410.1093/infdis/jit42423935205 12OrganisationW. H.WHO Information on Tuberculosis and Pandemic Influenza"/>
 <result pre="receptor-dependent pathwayThe Journal of Infectious Diseases2014209227027410.1093/infdis/jit42423935205 12OrganisationW. H.WHO Information on" exact="Tuberculosis" post="and Pandemic Influenza A (H1N1)2009Geneva, SwitzerlandWHOhttp://www9.who.int/tb/features_archive/h1n1/en/ 13LiJ.-Y.YouZ.WangQ.et al.The epidemic"/>
 <result pre="Influenza A (H1N1)2009Geneva, SwitzerlandWHOhttp://www9.who.int/tb/features_archive/h1n1/en/ 13LiJ.-Y.YouZ.WangQ.et al.The epidemic of 2019-novel-coronavirus (2019-nCoV)" exact="pneumonia" post="and insights for emerging infectious diseases in the futureMicrobes"/>
 <result pre="al.The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging" exact="infectious diseases" post="in the futureMicrobes and Infection2020222808510.1016/j.micinf.2020.02.00232087334 14BrodeS. K.JamiesonF. B.NgR.et al.Increased"/>
 <result pre="futureMicrobes and Infection2020222808510.1016/j.micinf.2020.02.00232087334 14BrodeS. K.JamiesonF. B.NgR.et al.Increased risk of mycobacterial" exact="infections" post="associated with anti-rheumatic medicationsThorax201570767768210.1136/thoraxjnl-2014-20647025911222 15OrganizationW. H.MERS situation update2020http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html 16OrganizationW."/>
 <result pre="associated with anti-rheumatic medicationsThorax201570767768210.1136/thoraxjnl-2014-20647025911222 15OrganizationW. H.MERS situation update2020http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html 16OrganizationW. H.Coronavirus" exact="disease" post="(COVID-19) pandemic2019https://www.who.int/emergencies/diseases/novel-coronavirus-2019 17RelloJ.TejadaS.UseroviciC.ArvanitiK.PuginJ.WatererG.Coronavirus disease 2019 (COVID-19): a critical care"/>
 <result pre="15OrganizationW. H.MERS situation update2020http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html 16OrganizationW. H.Coronavirus disease (COVID-19) pandemic2019https://www.who.int/emergencies/diseases/novel-coronavirus-2019 17RelloJ.TejadaS.UseroviciC.ArvanitiK.PuginJ.WatererG.Coronavirus" exact="disease" post="2019 (COVID-19): a critical care perspective beyond ChinaAnaesthia, Critical"/>
 <result pre="beyond ChinaAnaesthia, Critical Care &amp;amp; Pain Medicine202039316716910.1016/j.accpm.2020.03.001 18ChenJ.HuC.ChenL.TangL.ZhuY.XuX.Clinical Study of" exact="Mesenchymal" post="Stem Cell Treating Acute Respiratory Distress Syndrome Induced by"/>
 <result pre="&amp;amp; Pain Medicine202039316716910.1016/j.accpm.2020.03.001 18ChenJ.HuC.ChenL.TangL.ZhuY.XuX.Clinical Study of Mesenchymal Stem Cell Treating" exact="Acute" post="Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9)"/>
 <result pre="Pain Medicine202039316716910.1016/j.accpm.2020.03.001 18ChenJ.HuC.ChenL.TangL.ZhuY.XuX.Clinical Study of Mesenchymal Stem Cell Treating Acute" exact="Respiratory" post="Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection,"/>
 <result pre="18ChenJ.HuC.ChenL.TangL.ZhuY.XuX.Clinical Study of Mesenchymal Stem Cell Treating Acute Respiratory Distress" exact="Syndrome" post="Induced by Epidemic Influenza A (H7N9) Infection, a Hint"/>
 <result pre="Mesenchymal Stem Cell Treating Acute Respiratory Distress Syndrome Induced by" exact="Epidemic" post="Influenza A (H7N9) Infection, a Hint for COVID-19 Treatment2020Beijing,"/>
 <result pre="and lipid mediator networks in tuberculosisImmunological Reviews2015264126427510.1111/imr.1224925703565 20RothS.WhiteheadS.ThamthitiwatS.et al.Concurrent influenza" exact="virus infection" post="and tuberculosis in patients hospitalized with respiratory illness in"/>
 <result pre="lipid mediator networks in tuberculosisImmunological Reviews2015264126427510.1111/imr.1224925703565 20RothS.WhiteheadS.ThamthitiwatS.et al.Concurrent influenza virus" exact="infection" post="and tuberculosis in patients hospitalized with respiratory illness in"/>
 <result pre="networks in tuberculosisImmunological Reviews2015264126427510.1111/imr.1224925703565 20RothS.WhiteheadS.ThamthitiwatS.et al.Concurrent influenza virus infection and" exact="tuberculosis" post="in patients hospitalized with respiratory illness in ThailandInfluenza and"/>
 <result pre="al.Concurrent influenza virus infection and tuberculosis in patients hospitalized with" exact="respiratory" post="illness in ThailandInfluenza and Other Respiratory Viruses20137324424810.1111/j.1750-2659.2012.00413.x22817684 21CoD. O.HoganL."/>
 <result pre="in patients hospitalized with respiratory illness in ThailandInfluenza and Other" exact="Respiratory" post="Viruses20137324424810.1111/j.1750-2659.2012.00413.x22817684 21CoD. O.HoganL. H.KarmanJ.et al.Interactions between T cells responding"/>
 <result pre="clinical and immunological features and hypothesesCell Stress202044667510.15698/cst2020.04.21632292881 23HuiD. S. C.ZumlaA.Severe" exact="acute" post="respiratory syndromeInfectious Disease Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary tuberculosis"/>
 <result pre="and immunological features and hypothesesCell Stress202044667510.15698/cst2020.04.21632292881 23HuiD. S. C.ZumlaA.Severe acute" exact="respiratory" post="syndromeInfectious Disease Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary tuberculosis and"/>
 <result pre="features and hypothesesCell Stress202044667510.15698/cst2020.04.21632292881 23HuiD. S. C.ZumlaA.Severe acute respiratory syndromeInfectious" exact="Disease" post="Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary tuberculosis and SARS, ChinaEmerging"/>
 <result pre="C.ZumlaA.Severe acute respiratory syndromeInfectious Disease Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary" exact="tuberculosis" post="and SARS, ChinaEmerging Infectious Disease Journal2006124p. 707 25LowJ. G."/>
 <result pre="Disease Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary tuberculosis and SARS, ChinaEmerging" exact="Infectious" post="Disease Journal2006124p. 707 25LowJ. G. H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe"/>
 <result pre="Clinics of North America201933486988910.1016/j.idc.2019.07.00131668196 24WeiL.ArnaudF.Pan-HeZ.LinZ.Zhong-TaoX.FangT.Pulmonary tuberculosis and SARS, ChinaEmerging Infectious" exact="Disease" post="Journal2006124p. 707 25LowJ. G. H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe acute"/>
 <result pre="Infectious Disease Journal2006124p. 707 25LowJ. G. H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe" exact="acute" post="respiratory syndrome and pulmonary tuberculosisClinical Infectious Diseases20043812e123e12510.1086/42139615227635 26LiT.QiuZ.ZhangL.et al.Significant"/>
 <result pre="Disease Journal2006124p. 707 25LowJ. G. H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe acute" exact="respiratory" post="syndrome and pulmonary tuberculosisClinical Infectious Diseases20043812e123e12510.1086/42139615227635 26LiT.QiuZ.ZhangL.et al.Significant changes"/>
 <result pre="Journal2006124p. 707 25LowJ. G. H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe acute respiratory" exact="syndrome" post="and pulmonary tuberculosisClinical Infectious Diseases20043812e123e12510.1086/42139615227635 26LiT.QiuZ.ZhangL.et al.Significant changes of"/>
 <result pre="25LowJ. G. H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe acute respiratory syndrome and" exact="pulmonary" post="tuberculosisClinical Infectious Diseases20043812e123e12510.1086/42139615227635 26LiT.QiuZ.ZhangL.et al.Significant changes of peripheral T"/>
 <result pre="H.LeeC. C.LeoY. S.Guek-Hong LowJ.LeeC.-C.LeoY.-S.Severe acute respiratory syndrome and pulmonary tuberculosisClinical" exact="Infectious" post="Diseases20043812e123e12510.1086/42139615227635 26LiT.QiuZ.ZhangL.et al.Significant changes of peripheral T lymphocyte subsets"/>
 <result pre="syndrome and pulmonary tuberculosisClinical Infectious Diseases20043812e123e12510.1086/42139615227635 26LiT.QiuZ.ZhangL.et al.Significant changes of" exact="peripheral" post="T lymphocyte subsets in patients with severe acute respiratory"/>
 <result pre="changes of peripheral T lymphocyte subsets in patients with severe" exact="acute" post="respiratory syndromeThe Journal of Infectious Diseases2004189464865110.1086/38153514767818 27Nosocomial transmission of"/>
 <result pre="of peripheral T lymphocyte subsets in patients with severe acute" exact="respiratory" post="syndromeThe Journal of Infectious Diseases2004189464865110.1086/38153514767818 27Nosocomial transmission of Mycobacterium"/>
 <result pre="subsets in patients with severe acute respiratory syndromeThe Journal of" exact="Infectious" post="Diseases2004189464865110.1086/38153514767818 27Nosocomial transmission of Mycobacterium tuberculosis found through screening"/>
 <result pre="respiratory syndromeThe Journal of Infectious Diseases2004189464865110.1086/38153514767818 27Nosocomial transmission of Mycobacterium" exact="tuberculosis" post="found through screening for severe acute respiratory syndromeâ€&quot;Taipei, Taiwan,"/>
 <result pre="27Nosocomial transmission of Mycobacterium tuberculosis found through screening for severe" exact="acute" post="respiratory syndromeâ€&quot;Taipei, Taiwan, 2003MMWR Morbidity and Mortality Weekly Report2004531532132215103296"/>
 <result pre="transmission of Mycobacterium tuberculosis found through screening for severe acute" exact="respiratory" post="syndromeâ€&quot;Taipei, Taiwan, 2003MMWR Morbidity and Mortality Weekly Report2004531532132215103296 28AlfarajS."/>
 <result pre="and Mortality Weekly Report2004531532132215103296 28AlfarajS. H.Al-TawfiqJ. A.AltuwaijriT. A.MemishZ. A.Middle East" exact="respiratory" post="syndrome coronavirus and pulmonary tuberculosis coinfection: implications for infection"/>
 <result pre="Mortality Weekly Report2004531532132215103296 28AlfarajS. H.Al-TawfiqJ. A.AltuwaijriT. A.MemishZ. A.Middle East respiratory" exact="syndrome" post="coronavirus and pulmonary tuberculosis coinfection: implications for infection controlIntervirology2017601-2535510.1159/00047790828683463"/>
 <result pre="28AlfarajS. H.Al-TawfiqJ. A.AltuwaijriT. A.MemishZ. A.Middle East respiratory syndrome coronavirus and" exact="pulmonary" post="tuberculosis coinfection: implications for infection controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW."/>
 <result pre="H.Al-TawfiqJ. A.AltuwaijriT. A.MemishZ. A.Middle East respiratory syndrome coronavirus and pulmonary" exact="tuberculosis" post="coinfection: implications for infection controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW. H.OuC."/>
 <result pre="East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for" exact="infection" post="controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW. H.OuC. Q.HeJ. X.Clinical characteristics of"/>
 <result pre="controlIntervirology2017601-2535510.1159/00047790828683463 29GuanW. J.NiZ. Y.HuY.LiangW. H.OuC. Q.HeJ. X.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaThe New England Journal of Medicine20203821708172010.1056/NEJMoa200203232109013 30TadoliniM.CodecasaL."/>
 <result pre="tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 casesEuropean" exact="Respiratory" post="Journal202056110.1183/13993003.01398-2020 31HarrisJ.KeaneJ.How tumour necrosis factor blockers interfere with tuberculosis"/>
 <result pre="casesEuropean Respiratory Journal202056110.1183/13993003.01398-2020 31HarrisJ.KeaneJ.How tumour necrosis factor blockers interfere with" exact="tuberculosis" post="immunityClinical and Experimental Immunology201016111920491796 32OrganizationW. H.Addressing the Needs of"/>
 <result pre="control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisThe Lancet" exact="Respiratory" post="Medicine20142432133810.1016/s2213-2600(14)70031-124717628 34YasriS.WiwanitkitV.Tuberculosis and novel Wuhan coronavirus infection: pathological interrelationshipIndian"/>
 <result pre="coronavirus infection: pathological interrelationshipIndian Journal of Tuberculosis2020672p. 26410.1016/j.ijtb.2020.02.004 35GaoY.LiuM.ChenY.ShiS.GengJ.TianJ.Association between" exact="tuberculosis" post="and COVID-19 severity and mortality: a rapid systematic review"/>
 <result pre="from two cohortsPulmonology202026423324010.1016/j.pulmoe.2020.05.00232411943 37StochinoC.VillaS.ZucchiP.ParraviciniP.GoriA.RaviglioneM. C.Clinical characteristics of COVID-19 and active" exact="tuberculosis" post="co-infection in an Italian reference hospitalEuropean Respiratory Journal202056110.1183/13993003.01708-2020 38JohnR."/>
 <result pre="COVID-19 and active tuberculosis co-infection in an Italian reference hospitalEuropean" exact="Respiratory" post="Journal202056110.1183/13993003.01708-2020 38JohnR. H.DavidG. S.PhilipS. C.Pathogen transmission and clinic schedulingEmerging"/>
 <result pre="Respiratory Journal202056110.1183/13993003.01708-2020 38JohnR. H.DavidG. S.PhilipS. C.Pathogen transmission and clinic schedulingEmerging" exact="Infectious" post="Disease Journal2006121p. 159 39HardingE.WHO global progress report on tuberculosis"/>
 <result pre="Journal202056110.1183/13993003.01708-2020 38JohnR. H.DavidG. S.PhilipS. C.Pathogen transmission and clinic schedulingEmerging Infectious" exact="Disease" post="Journal2006121p. 159 39HardingE.WHO global progress report on tuberculosis eliminationThe"/>
 <result pre="schedulingEmerging Infectious Disease Journal2006121p. 159 39HardingE.WHO global progress report on" exact="tuberculosis" post="eliminationThe Lancet Respiratory Medicine202081p. 1910.1016/s2213-2600(19)30418-7 40AmimoF.LambertB.MagitA.What does the COVID-19"/>
 <result pre="Journal2006121p. 159 39HardingE.WHO global progress report on tuberculosis eliminationThe Lancet" exact="Respiratory" post="Medicine202081p. 1910.1016/s2213-2600(19)30418-7 40AmimoF.LambertB.MagitA.What does the COVID-19 pandemic mean for"/>
 <result pre="40AmimoF.LambertB.MagitA.What does the COVID-19 pandemic mean for HIV, tuberculosis, and" exact="malaria" post="control?Tropical Medicine and Health2020481p. 3210.1186/s41182-020-00219-6 41ManyazewalT.WoldeamanuelY.BlumbergH. M.FekaduA.MarconiV. C.The fight"/>
 <result pre="Medicine and Health2020481p. 3210.1186/s41182-020-00219-6 41ManyazewalT.WoldeamanuelY.BlumbergH. M.FekaduA.MarconiV. C.The fight to end" exact="tuberculosis" post="must not be forgotten in the COVID-19 outbreakNature Medicine202026681181210.1038/s41591-020-0917-1"/>
 <result pre="be forgotten in the COVID-19 outbreakNature Medicine202026681181210.1038/s41591-020-0917-1 42RusenI. D.Challenges in" exact="tuberculosis" post="clinical trials in the face of the COVID-19 pandemic:"/>
 <result pre="face of the COVID-19 pandemic: a sponsorâ€™s perspectiveTropical Medicine and" exact="Infectious" post="Disease202052p. 8610.3390/tropicalmed5020086 43OrganisationW. H.Coronavirus Disease (COVID-19) Pandemic2019https://www.who.int/topics/vaccines/en/ 44GrahamR. L.DonaldsonE."/>
 <result pre="a sponsorâ€™s perspectiveTropical Medicine and Infectious Disease202052p. 8610.3390/tropicalmed5020086 43OrganisationW. H.Coronavirus" exact="Disease" post="(COVID-19) Pandemic2019https://www.who.int/topics/vaccines/en/ 44GrahamR. L.DonaldsonE. F.BaricR. S.A decade after SARS:"/>
 <result pre="success and failure of BCG - implications for a novel" exact="tuberculosis" post="vaccineNature Reviews Microbiology20053865666210.1038/nrmicro121116012514 51AabyP.BennC. S.Saving lives by training innate"/>
 <result pre="vaccineProceedings of the National Academy of Sciences201210943173171731810.1073/pnas.1215761109 52Hollm-DelgadoM.-G.StuartE. A.BlackR. E.Acute" exact="lower" post="respiratory infection among Bacille Calmette-GuÃ©rin (BCG)-vaccinated childrenPediatrics20141331e73e8110.1542/peds.2013-221824379224 53PollardA. J.FinnA.CurtisN.Non-specific"/>
 <result pre="of the National Academy of Sciences201210943173171731810.1073/pnas.1215761109 52Hollm-DelgadoM.-G.StuartE. A.BlackR. E.Acute lower" exact="respiratory" post="infection among Bacille Calmette-GuÃ©rin (BCG)-vaccinated childrenPediatrics20141331e73e8110.1542/peds.2013-221824379224 53PollardA. J.FinnA.CurtisN.Non-specific effects"/>
 <result pre="the National Academy of Sciences201210943173171731810.1073/pnas.1215761109 52Hollm-DelgadoM.-G.StuartE. A.BlackR. E.Acute lower respiratory" exact="infection" post="among Bacille Calmette-GuÃ©rin (BCG)-vaccinated childrenPediatrics20141331e73e8110.1542/peds.2013-221824379224 53PollardA. J.FinnA.CurtisN.Non-specific effects of"/>
 <result pre="of vaccines: plausible and potentially important, but implications uncertainArchives of" exact="Disease" post="in Childhood2017102111077108110.1136/archdischild-2015-31028228501809 54CurtisN.SparrowA.GhebreyesusT. A.NeteaM. G.Considering BCG vaccination to reduce"/>
 <result pre="SARS coronavirus induce high levels of neutralizing antibodiesVirology20073621263710.1016/j.virol.2006.12.01117258782 60RobsonB.Computers and" exact="viral" post="diseases. Preliminary bioinformatics studies on the design of a"/>
 <result pre="Medicine202093p. 62310.3390/jcm9030623 62ErikssonK. K.MakiaD.MaierR.LudewigB.ThielV.Towards a coronavirus-based HIV multigene vaccineClinical &amp;amp;" exact="Developmental" post="Immunology2006132â€&quot;435336010.1080/1740252060057916817162377 63DiL.LiY.The risk factor of false-negative and false-positive for"/>
 <result pre="64LuL. L.SmithM. T.YuK. K. Q.et al.IFN-Î³-independent immune markers of Mycobacterium" exact="tuberculosis" post="exposureNature Medicine201925697798710.1038/s41591-019-0441-3 65WhittakerE.LÃ³pez-VarelaE.BroderickC.SeddonJ. A.Examining the complex relationship between tuberculosis"/>
 <result pre="Mycobacterium tuberculosis exposureNature Medicine201925697798710.1038/s41591-019-0441-3 65WhittakerE.LÃ³pez-VarelaE.BroderickC.SeddonJ. A.Examining the complex relationship between" exact="tuberculosis" post="and other infectious diseases in childrenFrontiers in Pediatrics2019723310.3389/fped.2019.00233 66YamasueM.KomiyaK.UsagawaY.UmekiK.NurekiS.-i.AndoM.Factors"/>
 <result pre="Medicine201925697798710.1038/s41591-019-0441-3 65WhittakerE.LÃ³pez-VarelaE.BroderickC.SeddonJ. A.Examining the complex relationship between tuberculosis and other" exact="infectious diseases" post="in childrenFrontiers in Pediatrics2019723310.3389/fped.2019.00233 66YamasueM.KomiyaK.UsagawaY.UmekiK.NurekiS.-i.AndoM.Factors associated with false negative"/>
 <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): the Perspectives of clinical immunologists from ChinaClinical"/>
 <result pre="(COVID-19): the Perspectives of clinical immunologists from ChinaClinical Immunology202021410.1016/j.clim.2020.108393 69SalehiS.AbediA.BalakrishnanS.GholamrezanezhadA.Coronavirus" exact="disease" post="2019 (COVID-19): a systematic review of imaging findings in"/>
</results>
